2026年以来,国内已有多款1 类创新药、全球首创产品、新适应症获批上市,同时有多个重磅品种申报上市获受理,覆盖肿瘤、自身免疫、妇科、代谢等核心赛道。如在3月3日,诺和诺德、礼来、亚虹医药等多家药企就相继宣布新药/新适应症在国内申报上市,或获得了《药品注册证书》。3月3日,CDE 显示,诺和诺德的司美格鲁肽注射液新适应症在国内申报上市,并拟纳入优先审评,适应症为用于治疗代谢相关脂肪性肝炎(MASH...
Source Link2026年以来,国内已有多款1 类创新药、全球首创产品、新适应症获批上市,同时有多个重磅品种申报上市获受理,覆盖肿瘤、自身免疫、妇科、代谢等核心赛道。如在3月3日,诺和诺德、礼来、亚虹医药等多家药企就相继宣布新药/新适应症在国内申报上市,或获得了《药品注册证书》。3月3日,CDE 显示,诺和诺德的司美格鲁肽注射液新适应症在国内申报上市,并拟纳入优先审评,适应症为用于治疗代谢相关脂肪性肝炎(MASH...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.